|  |  |  |
| --- | --- | --- |
| **Variable and Data Type** | **Operational Definition** | **Source** |
| Index dose amount | Index study medication dose | Medical and prescription claims |
| Dosing schedule | Average number of days between doses for patients with ≥2 prescriptions | Medical and prescription claims |
| Duration of therapy | Average number of days between first dose and last dose for patients with ≥2 treatments | Medical claims |
| Time to biosimilar initiation | Average number of days between first diagnosis (identified during the 360-day period prior to the first biosimilar claim) and first biosimilar claim | Medical claims |
| Time to therapy initiation  | Average number of days between first diagnosis (identified during the 360-day period prior to the first biosimilar claim) and first claim for rituximab (any product including rituximab-pvvr, rituximab reference medication, and other rituximab biosimilar) | Medical claims |

**Supplementary Table 1**. Definitions of Dosing and Treatment Patterns Variables

**Supplementary Table 2**. Treatment Utilization Patterns of Rituximab-pvvr in Patients with NHL and CLL

|  |  |  |
| --- | --- | --- |
| **Variables** | **NHL (N=193)** | **CLL (N=28)** |
| **N** | **Median** | **N** | **Median** |
| Index dose (mg) | 192 | 700 | 27 | 800 |
| Average dose (mg) | 192 | 700 | 27 | 800 |
| Dose schedule (days) | 74 | 21 | 11 | 23 |
| Duration of therapy (days) | 74 | 37 | 11 | 23 |
| Time to biosimilar initiation (days)\* | 193 | 95 | 27 | 258 |
| Time to therapy initiation (days)\* | 193 | 31 | 27 | 162 |

CLL, chronic lymphocytic leukemia; NHL, non-Hodgkin’s lymphoma.

\*360-day look-back period.